SCHEMBL25330627

SCHEMBL25330627

COC(=O)c1cn(CC2CC2)nc1C(=O)C(C)C

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 2/20 0.38
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 3/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 1/20 0.35
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PTGER4 P35408 1/20 0.34
LMNA P02545 1/20 0.34
CRHR1 P34998 3/20 0.34
TSHR P16473 1/20 0.33
RAB9A P51151 1/20 0.33
PDE10A Q9Y233 1/20 0.33
DRD3 P35462 1/20 0.33
POLB P06746 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
BTK Q06187 1/20 0.32
CRHR2 Q13324 1/20 0.32
OPRK1 P41145 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25331491 0.83 KDM4E (0.48) KDM4EALDH1A1KMT2AMEN1HTT
SCHEMBL25332781 0.80 PDE10A (0.35) MAP3K5CRHR1PDE10A
SCHEMBL25331868 0.79 CNR2 (0.39) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL25331830 0.78 KCNH2 (0.37) KDM4EALDH1A1TSHRDRD3BTK
SCHEMBL25332488 0.76 OPRK1 (0.36) ALDH1A1SMN1; SMN2BTKOPRK1
SCHEMBL25332610 0.75 ADORA2A (0.36) KDM4EALDH1A1KMT2AMEN1LMNA
SCHEMBL18138285 0.73 LMNA (0.35) MAP3K5KDM4EALDH1A1KMT2AMEN1
SCHEMBL18131175 0.72 ALDH1A1 (0.48) ALDH1A1KMT2AMEN1HTTSMN1; SMN2
SCHEMBL7514144 0.69 PDE10A (0.44) MAP3K5KDM4EALDH1A1CRHR1PDE10A
SCHEMBL3901793 0.69 GAA (0.43) KDM4EALDH1A1KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066369-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2025-02-27 US disclosed
EP-4460505-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES Nodthera Limited (GB) 2024-11-13 EP disclosed
WO-2023133271-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2023-07-13 WO disclosed
WO-2023133271-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2023-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066369-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES IL1B, NLRP3, IL1A MAP3K5 1470/4885KDM4E 4064/4885ALDH1A1 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.